July 1, 2010
Bookmark and Share  



This week’s postings include the following items:

• July 2010 HCV Advocate Newsletter:

  • “Is It Cost Effective to Treat HCV?”  A recap of a study conducted by Sammy Saab and colleagues looking at the cost effectiveness of treating HCV at various stages of the disease
  • EASL, Part 2 concentrating on the studies presented at EASL focusing on HCV polymerase inhibitors, NS4A inhibitors, and various all-oral combinations
  • Two perspectives on postponing HCV treatment until the new combinations of pegylated interferon, ribavirin and HCV protease inhibitors become available:
    • HealthWise: Waiting for Better HCV Treatment:  Living in the Gap,” and
    • “Editorial:  Is it Safe To Wait?”


• Other items posted to the HCV and HBV Advocate websites include:

  • Hepatitis Journal Review, by Liz Highleyman
  • HBV Journal Review, by Christine Kukka
  • Advocate HCV News Review
  • HCV Drug Pipeline - Updated June 30, 2010





Join me on Twitter -


Alan Franciscus
Executive Director, Hepatitis C Support Project
Editor-in-Chief, HCV Advocate www.hcvadvocate.org
Editor-in-Chief, HBV Advocate www.hbvadvocate.org


**Questions and Comments: Questions and/or comments can be directed to alanfranciscus@hcvadvocate.org

**To receive the eblast in your email inbox simply send an e-mail to: listserv@list.hcvadvocate.org with nothing in the subject line and the following in the message body: subscribe emailalert. Make sure your email address is all lower case.